158 million covered lives nationwide bring the FDA-cleared wearable Remote Electrical Neuromodulation (REN) device to coverage parity with leading prescription migraine drugs, following a wave of recent payer coverage expansions. BRIDGEWATER, N.J. and CAESAREA, Israel, July 9, 2026…
Source: prnewswire
Country: United States